• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用实验设计对一种产品的流通溶解方法进行稳健性测试,该产品中的活性成分具有明显不同的溶解性。

Robustness testing, using experimental design, of a flow-through dissolution method for a product where the actives have markedly differing solubility properties.

作者信息

Bloomfield M S, Butler W C

机构信息

Pharmaceutical Development Sciences, GlaxoWellcome, Temple Hill, Dartford, DA1 5AH, Kent, UK.

出版信息

Int J Pharm. 2000 Sep 25;206(1-2):55-61. doi: 10.1016/s0378-5173(00)00509-3.

DOI:10.1016/s0378-5173(00)00509-3
PMID:11058810
Abstract

The use of experimental design for the robustness testing of a flow-through dissolution method (Ph Eur/USP Apparatus 4) for atovaquone, one of the drug substances in a dual-active anti-malarial tablet formulation, Malarone tablets, is described. This procedure was developed to overcome the suppression of the atovaquone solubility, caused by the presence of the co-drug proguanil hydrochloride and potential imprecision due to the poor solubility of the coating material in the basic dissolution media employed. For this testing a quarter fractional two-level factorial design was applied, assessing six factors in sixteen experiments, with a further six centre points to assess natural experimental variation. Results demonstrate that the method is robust to small changes in all the main factors evaluated at sample times of 30 min or greater. At 15 min, variations in the concentration of sodium hydroxide in the dissolution media, peristaltic pump speed and flow rate were assessed as statistically significant. This observation is a result of the initial steepness of the dissolution release curve and hence these factors are now controlled routinely in the method. Release of this poorly soluble drug is limited at the 45 min time point (Q=75%) according to pharmacopoeial guidelines. The approach may be applied for other dissolution procedures.

摘要

描述了使用实验设计对一种流通溶解方法(欧洲药典/美国药典装置4)进行稳健性测试,该方法用于检测双活性抗疟片剂配方(玛拉隆片剂)中的一种原料药阿托伐醌。开发此程序是为了克服由于存在共同药物盐酸氯胍而导致的阿托伐醌溶解度抑制,以及由于包衣材料在所使用的碱性溶解介质中溶解度差而可能产生的不精确性。对于此测试,应用了四分之一分数二级析因设计,在16次实验中评估6个因素,还有另外6个中心点用于评估自然实验变异。结果表明,在30分钟或更长的取样时间下,该方法对所有评估的主要因素的微小变化具有稳健性。在15分钟时,溶解介质中氢氧化钠浓度、蠕动泵速度和流速的变化在统计学上被评估为显著。这一观察结果是溶解释放曲线初始陡峭度的结果,因此这些因素现在在该方法中被常规控制。根据药典指南,这种难溶性药物在45分钟时间点的释放有限(Q = 75%)。该方法可应用于其他溶解程序。

相似文献

1
Robustness testing, using experimental design, of a flow-through dissolution method for a product where the actives have markedly differing solubility properties.使用实验设计对一种产品的流通溶解方法进行稳健性测试,该产品中的活性成分具有明显不同的溶解性。
Int J Pharm. 2000 Sep 25;206(1-2):55-61. doi: 10.1016/s0378-5173(00)00509-3.
2
Bioavailability enhancement of atovaquone using hot melt extrusion technology.使用热熔挤出技术提高阿托伐醌的生物利用度
Eur J Pharm Sci. 2016 Apr 30;86:103-14. doi: 10.1016/j.ejps.2016.03.005. Epub 2016 Mar 9.
3
Atovaquone oral bioavailability enhancement using electrospraying technology.采用电喷雾技术提高阿托伐醌的口服生物利用度。
Eur J Pharm Sci. 2018 Jan 1;111:195-204. doi: 10.1016/j.ejps.2017.09.051. Epub 2017 Sep 30.
4
Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.malarone(阿托伐醌与盐酸氯胍):关于其治疗疟疾临床开发情况的综述。malarone临床试验研究组。
Am J Trop Med Hyg. 1999 Apr;60(4):533-41. doi: 10.4269/ajtmh.1999.60.533.
5
Evaluation of the H-point standard additions method (HPSAM) and the generalized H-point standard additions method (GHPSAM) for the UV-analysis of two-component mixtures.用于双组分混合物紫外分析的H点标准加入法(HPSAM)和广义H点标准加入法(GHPSAM)的评估。
J Pharm Biomed Anal. 1999 Oct;21(1):23-42. doi: 10.1016/s0731-7085(99)00111-9.
6
The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.阿托伐醌和氯胍用于治疗孕晚期孕妇单纯性恶性疟的药代动力学和药效学
Eur J Clin Pharmacol. 2005 Sep;61(8):573-82. doi: 10.1007/s00228-005-0969-7. Epub 2005 Jul 23.
7
Determination of atovaquone in tablets by differential pulse polarography.
Pharmazie. 2002 Jul;57(7):465-7.
8
Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model.阿托伐醌-氯胍(malarone)在人体激发试验模型中的因果预防疗效。
Trans R Soc Trop Med Hyg. 2001 Jul-Aug;95(4):429-32. doi: 10.1016/s0035-9203(01)90206-8.
9
Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro.阿托伐醌、氯胍和环氯胍对恶性疟原虫的体外药效学相互作用。
Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):331-7. doi: 10.1016/s0035-9203(03)90162-3.
10
Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.根据四种低溶解度药物的体外溶出数据预测其体内性能。
Pharm Res. 1999 Dec;16(12):1876-82. doi: 10.1023/a:1018959511323.

引用本文的文献

1
Hydrodynamic and species transfer simulations in the USP 4 dissolution apparatus: considerations for dissolution in a low velocity pulsing flow.USP4 溶出仪中的流体动力学和物质传递模拟:低速脉冲流溶出的考虑因素。
Pharm Res. 2010 Feb;27(2):246-58. doi: 10.1007/s11095-009-0010-4. Epub 2009 Dec 10.
2
In situ forming formulation: development, evaluation, and optimization using 3(3) factorial design.原位形成制剂:使用 3(3) 析因设计进行开发、评估和优化。
AAPS PharmSciTech. 2009;10(3):977-84. doi: 10.1208/s12249-009-9285-3. Epub 2009 Jul 28.
3
Comparison of dissolution profiles for sustained release resinates of BCS class I drugs using USP apparatus 2 and 4: a technical note.
使用美国药典装置2和4对BCS I类药物的缓释树脂酸盐溶出曲线进行比较:技术说明
AAPS PharmSciTech. 2008;9(3):769-73. doi: 10.1208/s12249-008-9110-4. Epub 2008 Jun 18.